10+ cancer types. One 6 ml blood draw.
TEPScan is a multi-cancer test. Its first Research Use Only launch in India covers lung (NSCLC) and head & neck cancer, with more modules in validation.
Last updated
Cancer modules
Lung (NSCLC) cancer
First RUO launchNon-small cell lung cancer is the focus of the published 11-gene platelet signature.
Head & neck cancer
First RUO launchPlanned for Care Onco’s first Research Use Only launch in India, alongside NSCLC.
Breast cancer
In validation150 breast validations, including a study with Stavanger University Hospital, Norway.
Ovary cancer
In validationPart of the TEPScan multi-cancer programme.
Prostate cancer
In validationPart of the TEPScan multi-cancer programme.
Kidney cancer
In validationPart of the TEPScan multi-cancer programme.
Colon cancer
In validationPart of the TEPScan multi-cancer programme.
Pancreas cancer
In validationPart of the TEPScan multi-cancer programme.
Thyroid cancer
In validationPart of the TEPScan multi-cancer programme.
Soft tissue cancer
In validationPart of the TEPScan multi-cancer programme.
Gastric cancer
In validationPart of the TEPScan multi-cancer programme.
Why early detection matters across cancer types
Around 75% of cancers are detected late, after they have spread. Finding cancer at Stage I or II usually means simpler treatment, lower costs and much better outcomes. Yet most cancers have no affordable, non-invasive screening test.Source: WHO, Cancer fact sheet
TEPScan reads one shared signal, cancer-induced changes in platelet RNA, rather than searching for each tumour separately. That is why a single 6 ml blood draw can be tested against several cancer modules.
How modules are added
Each module is trained and validated on samples from partner cancer centres before release. NSCLC and head & neck cancer will launch first as Research Use Only tests in India, followed by a three-cancer kit. Breast cancer has completed 150 validations, including a study with Stavanger University Hospital in Norway.
Learn how the test works or read the evidence.
Validate a module with us.
Cancer centres and pharma teams: partner on the next TEPScan modules.